Merrimack Pharmaceuticals, Inc.

Silver Creek Pharmaceuticals, Inc.

Rubius Therapeutics, Inc.

Thomas Joseph Wickham

Ulrik Bjerl Nielsen

Birgit Schoeberl

Matthew D Onsum

Brian Harms

Bryan Linggi

Byron DeLaBarre

Shaun M Lippow

Bart S Hendriks

Elena Geretti

Joseph G Reynolds

Dmitri B Kirpotin

Daryl C Drummond

Samuel V Agresta

Helen Lee

Daniel F Gaddy

Kenneth J Olivier, Jr

Stephan Klinz

Victor Mandla Moyo

Sivan Elloul

Christopher W Espelin

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-specific fusion proteins

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell. The engineered enucleated cells of the present disclosure are useful in methods of activating NK cells and/or CD8+T-cells in a subject in need thereof, such as subjects having cancer or an infectious disease, and in particular cancers or infectious diseases characterized by downregulation of MHC Class I presentation.

Therapeutic cell systems and methods for treating cancer and infectious diseases

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

Compositions and methods for non-invasive imaging

Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Combination therapy for treating HER2-positive cancers

Method of treating myocardial infarction by administering a bi-specific fusion protein

Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.

Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Bi-specific fusion proteins for tissue repair

Growing community of inventors

Groton, MA, United States of America

Thomas Joseph Wickham